Kornimate/medical-research-clean huggingface dataset:
effects of kegel exercises with and without myofascial release in chronic pelvic pain

Conditions: Chronic Pelvic Pain Syndrome

Summary: study will be a randomized control trial to check the effects of kegel exercise with and without myofascial release on chronic pelvic pain in females so that we can examine the effect of above techniques on pain, function and quality of life in chronic pelvic pain females.non-probability convenience sampling technique will be used, subject following eligibility criteria from dhq hospital layyah will be randomly allocated in two groups. group a participants will be given kegel exercise with myofascial release, group b participants will be given kegel exercise for 3 weeks. assessment will be done via, numeric pain rating scale and pelvic floor impact questionnaire (pfiq) and functional pelvic pain scale

chronic pelvic pain (cpp), defined as a noncyclical pain lasting for more than 6 months can lead to lower physical performance and quality of life in women. in this study the effects of kegel exercise with and without myofascial release in chronic pelvic pain population will be analyzed. this study will be a randomized clinical trial. kegel exercise and myofasical release would be administered to the chronic pelvic pain females. subjects meeting the predetermined inclusion criteria will be divided into two groups. assessment will be done using numeric pain rating scale (npr), pelvic floor impact questionnaire (pfiq) and functional pelvic pain scale (fpps). subjects in one group will be treated with kegel exercise with myofascial release, and the other will be treated with kegel exercise only. each subject will receive a total 12 treatment sessions, with 04 treatment sessions per week. measurements will be recorded at start and end of treatment session. recorded values will be analyzed for any change using spss.

Eligibility criteria:
inclusion criteria: * • age 25-55 * record of cpps for more than 6 months. * complete gynaecological consultation with necessary workup. * chronic pelvic pain associated with gynaecological issue. * patients who have tenderness upon palpation are included, suggesting that the trigger points are painful. * patient that can't cope with their daily activities exclusion criteria: * acute active infection * malignancy * active pregnancy * pudendal nerve entrapment syndrome. * not simultaneously partaking in pelvic floor physical therapy. * no evoked tenderness upon palpation of levator ani sling at examination.
relapse myeloma; cyclofosfamide; bortezomib; maintenance

Conditions: Multiple Myeloma

Summary: bortezomib and cyclophosphamide in combination with dexamethasone has already demonstrated high response rates in refractory multiple myeloma. low dose continuous cyclophosphamide, also called metronomic scheduling, minimize toxic side effects and eliminate the obligatory rest periods. combining cyclophosphamide with bortezomib might target distinct aspects of a myeloma functionality. the objectives of the present study are whether patients with refractory or relapsed multiple myeloma after reinduction with bortezomib, cyclophosphamide and dexamethasone will benefit from maintenance therapy with bortezomib and cyclophosphamide with acceptable side-effects. recently two studies have shown with thalidomide that maintenance therapy might improve efs and one study also the os.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * stage ii-iii multiple myeloma * relapse or primary refractory disease after initial chemotherapy * who performance status 0 - 2 * life expectancy of at least 6 weeks * anc (absolute neutrophil count) ≥ 1.0x109/l(or ≥ 0.5x109/l, if due to bone marrow infiltration by malignancy) * platelet count ≥ 75x109/l or ≥ 50x109/l, if due to bone marrow infiltration by malignancy) * written informed consent (present in patient's file) * patient is able and willing to use adequate contraception during therapy and for at least 1 month after study * patient has the ability to understand the requirements of the study exclusion criteria: * previous treatment with bortezomib * urine production \< 1.5 l/24h * pre-existent polyneuropathy (grade 2 or higher, according to ctcae 3.0) * pregnancy or positive pregnancy tests during study and for 1 month after final dose of thalidomide * history of active malignancy during the past 5 years with the exception of basal carcinoma of the skin) * active uncontrolled infections * additional uncontrolled serious medical or psychiatric illness

Keywords: bortezomib cyclophosphamide dexamethason multiple myeloma
safety and efficacy evaluation of high intensity focused ultrasound device in eyebrow lifting

Conditions: Skin Laxity; Wrinkles; Facial Wrinkles and Rhytides Reduction

Summary: the goal of this clinical trial is to assess the safety and efficacy of the high-intensity focused ultrasound (hifu) device, ultraformer mpt (uf4-m400), developed by classys inc., for eyebrow lifting. this study is a prospective, multicenter, evaluator-blinded, randomized, non-treatment-controlled, superiority clinical trial. the main questions the study seeks to answer are: does the ultraformer mpt device effectively lift eyebrows? is the safety profile of the ultraformer mpt device acceptable? researchers will compare the investigational device to a non-treatment control group to determine whether the hifu device demonstrates superiority in eyebrow lifting outcomes. participant details: participants will receive a single treatment session using the investigational device or be assigned to the non-treatment control group. follow-up will occur over 3 months to evaluate the effectiveness and safety of the treatment. outcomes: primary outcome: eyebrow lifting improvement, assessed through standardized photographic evaluation and other aesthetic measurement tools. secondary outcomes: participant satisfaction using the global aesthetic improvement scale (gais) and pain assessment using a visual analog scale (vas). safety measures: monitoring for adverse events (aes) and serious adverse events (saes) throughout the study period. this trial aims to provide robust evidence supporting the use of the ultraformer mpt for non-invasive eyebrow lifting.


Eligibility criteria:
inclusion criteria: 1. age: 20 to 65 years old at the time of consent. 2. condition: forehead skin laxity with forehead lines grading scale score of 1-3. 3. consent: ability to understand trial details, voluntarily participate, and comply with treatment and follow-up. exclusion criteria: 1. skin conditions: hyperpigmentation, tattoos, scars, active skin diseases, or other conditions (e.g., eczema, psoriasis, vitiligo) in the treatment area that may affect efficacy or increase risk. 2. medical devices or implants: presence of metal implants or embedded electronic devices in the treatment area. 3. health conditions: severe dysfunction of vital organs (e.g., heart, liver, kidneys), autoimmune diseases, or uncontrolled diabetes. 4. medications: recent use of anti-thrombotic agents, nsaids, or other drugs affecting coagulation within one week before screening. 5. prior treatments: use of fillers (e.g., hyaluronic acid, collagen) or cosmetic procedures (e.g., laser therapy, botulinum toxin) in the treatment area within the specified timeframes. 6. pregnancy: women who are pregnant, nursing, or not using birth control during the trial.

Keywords: high intensity focused ultrasound hifu ultraformer mpt ultraformer mpt eyebrow eyebrow lifting
evaluation of peripartum blood loss and postpartum anaemia in macrosomia & gemini

Conditions: Bloodloss in Pregnancy

Summary: anaemia in pregnant women occurs at a haemoglobin (hb) concentration \<11 g/dl and treatment is essential to prevent increased maternal morbidity, fetal morbidity and mortality. studies show a distinct risk of haemorrhage in pregnant women due to increased uterine dilatation, due to twins or macrosomic singletons. currently, prepartum anaemia management, the influence of anaemia and the administration of foreign blood concentrates are insufficiently studied. the investigators intend to conduct a monocentric retrospective analysis of this subcohort.

patient blood management is essentially based on three pillars, and a meta-analysis has already shown that consistent use can reduce transfusions and mortality. the who defines anaemia in pregnant patients as a haemoglobin (hb) concentration \<11 g/dl. treatment of iron deficiency anaemia is essential because data show that iron deficiency anaemia is associated with increased maternal morbidity, fetal morbidity and mortality. studies show a separate risk of bleeding in pregnant women due to increased uterine prolapse, for example in twin pregnancies or macrosomic singletons. at present, the prepartum anaemia management of patients, the influence of anaemia and the administration of foreign blood concentrates are insufficiently studied, which the investigators intend to investigate.

Eligibility criteria:
inclusion criteria: * pregnancy exclusion criteria: * pre-existing coagulation disorder
a study of tcd601 (siplizumab) in new onset type 1 diabetes patients

Conditions: Diabetes Mellitus, Type 1

Summary: the goal of this study is to determine if treatment with tcd601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.


Eligibility criteria:
inclusion criteria: * able to understand the study requirements and provide written informed consent before any study assessment is performed * male or female patients ≥ 18 to 45 years of age * a diagnosis of type 1 diabetes exclusion criteria: * women who are pregnant, lactating, or planning on pregnancy during the study * history of cancer * history of heart disease * recent infection
indocyangreen elimination in cirrhosis and acute liver failure

Conditions: Acute Liver Failure; Liver Cirrhosis

Summary: indocyangreen (icg)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion. the icg-clearance will be evaluated as a prognostic marker in liver disease.

patients with acute liver failure or advanced liver disease will be studied. icg-clearance will be correlated with established clinical scores and outcome.

Eligibility criteria:
inclusion criteria: * acute liver failure or end-stage liver disease * normal hepatic perfusion by doppler ultrasound exclusion criteria: * portal vein thrombosis * allergy to icg or iodine * thyroid disease

Keywords: icg clearance liver cirrhosis acute liver failure prognosis
rtms and functional paralysis

Conditions: Psychogenic Paralysis

Summary: psychogenic paralysis presents a real treatment challenge. despite psychotherapy, physiotherapy, antidepressants, acupuncture or hypnosis, the outcome is not always satisfactory with persistent symptoms after long-term follow-up. in a preliminary retrospective study on 70 patients with psychogenic paralysis (44f/26m, mean age : 24.7 ± 16.6 ys), repetitive transcranial magnetic stimulation (rtms) delivered over the motor cortex at low frequency was effective in 89% of cases (recovery: n=53, improvement: n=9), with an immediate or quasi-immediate recovery in 73% of patients (n=51). we suggest that the dramatic improvement of psychogenic paralysis after rtms could be due to the restoration of an appropriate cerebral connectivity by activating a suppressed motor cortex. nevertheless, the possibility of a placebo effect cannot be ruled out. a prospective multicentric (rouen, caen) randomized controlled trial versus placebo will be done for 94 patients with psychogenic paralysis, 1- to evaluate rtms efficacy for paralysis at short and long term follow-up, and 2- to confirm rtms safety. two rtms sessions will be performed at d0 and d1 (120 pulses over 2 days, delivered over the motor cortex at 2 hz) with an active or a sham coil. post-rtms assessment will evaluate 1- the degree of the paralysis at d2 (quantified by a videotape) and d60 (quantified by an interview and a standardized examination), 2- the number and gravity of side effects. if psychogenic paralysis improvement by motor cortex rtms is confirmed, rtms could be considered a useful early therapeutic option.


Eligibility criteria:
inclusion criteria: * age \> 14 years old * psychogenic paralysis according to the dsm-iv-r exclusion criteria: * contra-indication of rtms * pregnancy or breast-feeding * previous history of epilepsia * previous session of rtms (for any indication)
safety and tolerability study which evaluate intravesical instillation with mitomycin c mixed with tc-3 drug retaining hydrogel device in patients with muscle invasive bladder cancer

Conditions: Carcinoma of Urinary Bladder, Invasive

Summary: the purpose of this study is to evaluate the safety of intravesical instillation of tc-3 hydrogel disposable device for retention of mitomycin c chemotherapeutic drug in the urinary bladder.

non-muscle-invasive bladder cancer is mainly treated by tumor resection (trans urethral resection - tur), followed by series of intravesical instillations of prophylactic chemotherapeutic drugs as mitomycin c (mmc).this treatment approach is limited due to rapid dilution the chemotheraputic drug by the incoming urine and clearance by urination. theracoat core technology is based on a reverse thermal (low viscosity at 5°c) degradable gel (tc-3)for mmc retention in the urinary bladder. prior to instillation, the tc-3 hydrogel,in a liquid state, is mixed with mmc.tc-3 mixed with mmc is instilled to the bladder by a catheter.following gel insertion to the bladder, the gel solidifies and forms a drug reservoir inside the bladder. upon contact with urine the gel dissolves and is cleared out from the bladder. intravesical mmc using theracoat gel is expected to increase treatment efficiency due to prolongation of treatment duration and consequently improving bladder exposure to mmc.

Eligibility criteria:
inclusion criteria: * signed informed consent form. * patients with bladder cancer designated to undergo radical cystectomy exclusion criteria: * sensitivity to mmc * acute urinary tract infection (uti) * upper urinary tract obstruction. * patient received neoadjuvant treatment previous to radical cystectomy * pregnant women as diagnosed by beta - hcg, or women that are suspected to be pregnant * breastfeeding women

Keywords: non muscle invasive bladder cancer carcinoma of urinary bladder, invasive intravesical instillation mitomycin c hydrogel reverse thermal gelation drug retention radical cystectomy
dupilumab compassionate use study

Conditions: Asthma

Summary: this is a single patient expanded access, compassionate and non-emergency use study that provides patients with severe asthma, who do not qualify for ongoing clinical trials with dupilumab, access to this investigational treatment.

this study is being undertaken to determine whether dupilumab has efficacy in extremely severe asthma, and to allow a very severe asthma patient, who has been tried on nearly every immunosuppressive drug, early access to a potentially effective therapy. the patient will continue in the study indefinitely. safety will be evaluated and serious adverse events will be reported.

Eligibility criteria:
inclusion criteria: * sever systemic corticosteroid dependent asthma for more than 5 years exclusion criteria: * disease other than asthma * circulation eosinophils more than 1500/ul * current smoker or more than 10 pack years this is a single-patient study. the university of pittsburgh site is not enrolling new patients.
effects of walking training on different surfaces on walking ability in ambulatory patients with spinal cord injury

Conditions: Spinal Cord Injuries; Rehabilitation

Summary: the study compares effects of 4-week walking training program on a walking track with difference surface \[wtds\] and a firm ground on functional ability of ambulatory individuals with incomplete spinal cord injury \[isci\], using within- and between-group comparisons.


Eligibility criteria:
inclusion criteria: 1. age at least 18 years 2. having an incomplete sci (the american spinal cord injury association (asia) impairment scale or ais c or d) (kirshblum et al., 2011) 3. at a sub-acute or chronic stage of injury (post injury time: pit \> 3 months) (wirth et al., 2008; blackwell et al., 2001) 4. able to walk with or without a walking device for at least 10m (behrman et al., 2005; lam et al., 2008; jackson et al., 2008) 5. having a body mass index (bmi) between 18.5-29.9 kg/m2 (woo et al., 2007) exclusion criteria: 1. having an sci from a progressive disease such as multiple sclerosis or malignancy 2. having other medical conditions that might affect ambulatory ability, such as pain in the musculoskeletal system with an intensity of pain more than 5 out of 10 on a numeric rating pain scale (dijkers, 2010), deformities of the spine and lower extremities (i.e. scoliosis, kyphosis, and equinovarus) and other neurological or other medical disorders (thromboembolism, autonomic dysreflexia). 3. severe spasticity of the lower extremities (modified ashworth scale (mas) more than 2) (bohannon \& smith, 1987; scivoletto et al., 2008).

Keywords: rehabilitation surfaces walking spinal cord injury
prospective observational cohort study on mother to child transmission hiv1/hiv2 and prevention

Conditions: Mother to Child Transmission of HIV

Summary: the purpose of this study is to describe over time the rate of mother to child transmission of hiv and its prevention (pmtct), to identify risk factors for transmission and to evaluate the safety of pmtct strategies on outcome of pregnancy and in children not infected with hiv

the co1-epf prospectively enrolled hiv-infected women who deliver in 25 centers throughout france, except in case of refusal. maternal clinical, biological and therapeutic data before and during pregnancy are collected at delivery. the children are examined clinically and biologically at birth, 1, 3, 6, 12 and 24 months. an infant is considered as non infected if two virologic tests are negative beyond the prophylactic treatment or serology is negative after 18 months. an infant is considered as infected if hiv1 is detected by virologic tests on two occasions (polymerase chain reactions, viral culture or p24 antigenemia) and if anti-hiv1 antibodies (elisa and western blot) persist after 18 months of age. follow up is stopped at 24 months for uninfected infants whereas infected infants are enrolled in the co10 epf paediatric cohort. no specific recommendation for hiv treatment and obstetrical care are made for women and children included in the cohort, although national guidelines for prevention of mtct are regularly published and updated. frozen maternal samples blood and plasma are stored in a centralized laboratory. a research of patients patients lost to follow-up (last visit \<24 months) and monitoring is performed regularly in all sites.

Eligibility criteria:
inclusion criteria: * pregnant women \>= 18 years * infected with hiv1 and/or hiv2 exclusion criteria: -

Keywords: hiv pregnancy prevention of mother-to-child transmission
observational study of dental outcomes in head and neck cancer patients

Conditions: Head and Neck Cancer; Dental Disease; Xerostomia; Osteoradionecrosis

Summary: the purpose of this study is to measure the two-year rate of tooth loss in patients who have received external beam radiation therapy with curative intent for head and neck cancer. the study will also evaluate the sequelae of radiation therapy and oral complications that may occur as a result to receiving radiation therapy.

this is a prospective cohort study to document dental and other oral outcomes in patients who receive external beam radiation therapy with curative intent, as part of clinical care for a head and neck cancer. five hundred and seventy-five participants will be enrolled. all study participants will receive a baseline oral examination prior to the start of radiation therapy. follow-up examinations and data collection will be conducted at six-month intervals up to 2 years after the start of radiation therapy. the primary outcome will be the two-year rate of tooth loss. secondary outcomes will include measures of dental caries, periodontal health, salivary flow, and exposed bone/osteoradionecrosis. the proposed research will provide more information to inform the community about the sequelae of radiation therapy (rt) in head and neck cancer patients, to refine current guidelines and to design future studies on the dental management of these patients.

Eligibility criteria:
inclusion criteria: * aged 18 years and older; * willing and able to provide signed and dated consent form; * diagnosed with head and neck squamous cell carcinoma (scc) or a salivary gland cancer (sgc), and intends to receive external beam radiation therapy (rt) with curative intent (tumor eradication), with or without concomitant chemotherapy; or * diagnosed with a non-scc, non-sgc malignancy of the head and neck region, and intends to receive rt, with or without concomitant chemotherapy. the subject must be expected to receive at least 4500 cgy to one of the following sites: 1. base of tongue 2. buccal/labial mucosa 3. epiglottis 4. floor of mouth 5. gingiva/alveolar ridge 6. hard palate 7. hypopharynx 8. larynx 9. lip 10. mandible 11. maxilla 12. maxillary sinus 13. nasal cavity 14. nasopharynx 15. neck 16. oral cavity 17. oral tongue 18. oropharynx 19. paranasal sinus/orbit 20. parotid gland 21. pharynx 22. retromolar trigone 23. soft palate 24. sublingual gland 25. submandibular gland 26. tonsil; * at least 1 natural tooth remaining or expected to remain in the mouth after completion of the pre-rt dental extractions, if any; * willing to comply with all study procedures; * willing to participate for the duration of the study. exclusion criteria: * receiving palliative rt; * history of prior curative rt to the head and neck region to eradicate a malignancy; * incarcerated at time of screening; * anything that would place the subject at increased risk or preclude the subject's full compliance with or completion of the study.

Keywords: head and neck cancer radiation therapy
efficacy of seroquel sr in combination with an antidepressant in treatment of major depressive disorder

Conditions: Major Depressive Disorder

Summary: to evaluate the efficacy of quetiapine fumarate sustained release (seroquel sr™) in combination with an antidepressant versus an antidepressant alone in patients with major depressive disorder. please note: seroquel sr and seroquel xr refer to the same formulation. the sr designation was changed to xr after consultation with fda.


Eligibility criteria:
inclusion criteria: * male or female aged 18 to 65 years * a documented diagnosis of major depressive disorder exclusion criteria: * patients with a dsm iv axis i disorder other than mdd within 6 months of enrolment * patients with a diagnosis of dsm iv axis ii disorder which has a major impact on the patient's current psychiatric status * patients whose current episode of depression exceeds 12 months or is less than 4 weeks prior to enrolment

Keywords: major depressive disorder mdd